AbbVie Inc. $ABBV Stock Holdings Lifted by Allworth Financial LP

Allworth Financial LP increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 8.4% during the fourth quarter, Holdings Channel reports. The fund owned 264,206 shares of the company’s stock after acquiring an additional 20,372 shares during the quarter. Allworth Financial LP’s holdings in AbbVie were worth $60,368,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Freemont Management S.A. boosted its stake in AbbVie by 1,030.0% in the 4th quarter. Freemont Management S.A. now owns 11,300 shares of the company’s stock worth $2,582,000 after purchasing an additional 10,300 shares during the period. Rayburn West Financial Services LLC acquired a new stake in AbbVie during the 4th quarter valued at $4,026,000. Cardinal Point Capital Management ULC lifted its holdings in shares of AbbVie by 4.6% in the fourth quarter. Cardinal Point Capital Management ULC now owns 6,870 shares of the company’s stock valued at $1,570,000 after purchasing an additional 300 shares in the last quarter. Atria Investments Inc boosted its position in shares of AbbVie by 0.7% in the fourth quarter. Atria Investments Inc now owns 168,667 shares of the company’s stock worth $38,539,000 after buying an additional 1,159 shares during the period. Finally, Catalyst Financial Partners LLC boosted its position in shares of AbbVie by 5.8% in the fourth quarter. Catalyst Financial Partners LLC now owns 14,233 shares of the company’s stock worth $3,252,000 after buying an additional 785 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ABBV. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Berenberg Bank set a $275.00 target price on AbbVie in a report on Tuesday, January 20th. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Finally, Morgan Stanley raised their price target on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $252.90.

AbbVie Price Performance

Shares of NYSE ABBV opened at $208.39 on Thursday. AbbVie Inc. has a one year low of $176.57 and a one year high of $244.81. The business’s 50-day moving average price is $211.23 and its two-hundred day moving average price is $220.29. The company has a market capitalization of $368.17 billion, a P/E ratio of 102.65, a price-to-earnings-growth ratio of 0.72 and a beta of 0.32.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period last year, the business earned $2.46 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 14.32 EPS for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s dividend payout ratio is 340.89%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New immunology data and an upgraded 2026 earnings outlook are reinforcing confidence in AbbVie’s growth trajectory and valuation. A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook
• Positive Sentiment: Analyst commentary continues to lean constructive, with recent coverage highlighting AbbVie as an attractive long-term healthcare name and pointing to a higher price target from Evercore ISI. Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term
• Positive Sentiment: Multiple recent articles argue AbbVie’s growth engine is “firing,” with bullish takes centered on its expanding drug portfolio and rising dividend, both supportive of investor sentiment. 3 Reasons to Buy AbbVie Stock (ABBV) Like There’s No Tomorrow
• Neutral Sentiment: AbbVie appointed Kelly Sanderson Schrems as UK VP and General Manager, a routine leadership move that is unlikely to materially move the stock on its own. AbbVie Appoints Kelly Sanderson Schrems as UK VP and General Manager
• Neutral Sentiment: Shareholders backed directors and maintained the governance structure at the annual meeting, which removes uncertainty but is not a major new catalyst. AbbVie Shareholders Back Directors, Maintain Governance Structure
• Neutral Sentiment: Zacks and other commentary remain supportive, but this is mostly reinforcing existing optimism rather than introducing a major new catalyst. The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.06% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.